[Biomarkers of prostate cancer. A review]. / Biomarker della neoplasia prostatica. Una review.
Minerva Urol Nefrol
; 62(2): 163-78, 2010 Jun.
Article
in It
| MEDLINE
| ID: mdl-20562797
ABSTRACT
Prostate cancer has the highest tumour incidence in the male population and represents 9.2% of cancer-related deaths. The most commonly used screening technique up to the present has been serum measurement of PSA which has led to a marked increase in the number of prostate cancer cases diagnosed every year. Nevertheless PSA in the early diagnosis of prostate cancer has many limitations. It can lead to a very high number of unnecessary biopsies in patients with benign prostate hyperplasia and, in addition, may also lead to an overdiagnosis and overtreatment of clinically insignificant neoplasias. Moreover many neoplasias are already present with PSA within normal limits. It is clear, therefore, that new biomarkers for the diagnosis and follow-up of prostate cancer have to be developed. We present a review of the literature in which we have analysed the most promising biomarkers in terms of sensitivity and diagnostic specificity for prostate cancer and which are currently under study, analysing recent developments and future prospects.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
Type of study:
Screening_studies
Limits:
Humans
/
Male
Language:
It
Journal:
Minerva Urol Nefrol
Journal subject:
NEFROLOGIA
/
UROLOGIA
Year:
2010
Type:
Article
Affiliation country:
Italy